Literature DB >> 31344005

Prophylactic Versus Postfracture Stabilization for Metastatic Lesions of the Long Bones: A Comparison of 30-day Postoperative Outcomes.

Jad M El Abiad1, Micheal Raad, Varun Puvanesarajah, Sandesh S Rao, Carol D Morris, Adam S Levin.   

Abstract

INTRODUCTION: The goals of orthopaedic treatment for most patients with osseous metastases are to control pain, maintain function, and maximize quality of life and time at home. The aim of this study was to determine differences in 30-day postoperative morbidity and mortality between patients who underwent prophylactic versus postfracture stabilization for metastatic lesions of long bones.
METHODS: The American College of Surgeons National Surgical Quality Improvement Program database was queried for patients who underwent prophylactic fixation (n = 461) or postfracture stabilization (n = 856) for pathologic fractures because of metastatic lesions of long bones from 2006 to 2016. The groups were compared with respect to several potential confounders using Student t, Kruskal-Wallis, and χ tests. Logistic and Poisson regression models (inclusion threshold of P < 0.1) were used to assess the associations of functional status with outcomes. The alpha level was set at 0.05.
RESULTS: Prophylactic fixation was associated with a lower risk of major medical complications (odds ratio = 0.64; 95% confidence interval [CI], 0.45 to 0.93; P = 0.02), discharge to a care facility rather than home (odds ratio = 0.48; 95% CI, 0.36 to 0.63; P < 0.01), and lower risk of a longer hospital stay (incidence risk ratio = 0.86; 95% CI, 0.74 to 0.96; P = 0.01) compared with postfracture stabilization. No significant difference was found in the risk of unplanned revision surgery or 30-day postoperative mortality between the two groups.
CONCLUSION: Although prevention of pathologic fractures caused by metastatic disease may not always be possible, patients who underwent prophylactic stabilization had a lower risk of major complications within 30 days postoperatively and shorter hospital stays compared with patients who underwent postfracture stabilization. LEVEL OF EVIDENCE: Level IV, retrospective cohort.

Entities:  

Mesh:

Year:  2019        PMID: 31344005     DOI: 10.5435/JAAOS-D-18-00345

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  6 in total

1.  Evaluating factors affecting length of hospital stay in patients with metastatic bone tumors.

Authors:  Nicole Hughes; Jacob Birlingmair; Jordan Baker; Grace Tideman; Kyle Sweeney
Journal:  J Orthop       Date:  2022-01-13

2.  Outcomes and prognostic factors after surgery for bone metastases in the extremities and pelvis: A retrospective analysis of 140 patients.

Authors:  Thore Raschka; Sebastian Weiss; Alonja Reiter; Alexej Barg; Carsten Schlickewei; Karl-Heinz Frosch; Matthias Priemel
Journal:  J Bone Oncol       Date:  2022-04-06       Impact factor: 4.491

3.  CORR Insights®: Thirty-day Postoperative Complications After Surgery for Metastatic Long Bone Disease Are Associated With Higher Mortality at 1 Year.

Authors:  Adam S Levin
Journal:  Clin Orthop Relat Res       Date:  2020-02       Impact factor: 4.755

4.  Thirty-day Postoperative Complications After Surgery For Metastatic Long Bone Disease Are Associated With Higher Mortality at 1 Year.

Authors:  Bas J J Bindels; Quirina C B S Thio; Kevin A Raskin; Marco L Ferrone; Santiago A Lozano Calderón; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2020-02       Impact factor: 4.755

5.  A Case of Lower Extremity Weakness with Foot Drop Following Intramedullary Nailing of a Pathologic Femoral Fracture.

Authors:  Charles A Gusho
Journal:  Cureus       Date:  2020-01-04

6.  Do Disparities in Wait Times to Operative Fixation for Pathologic Fractures of the Long Bones and 30-day Complications Exist Between Black and White Patients? A Study Using the NSQIP Database.

Authors:  Micheal Raad; Varun Puvanesarajah; Kevin Y Wang; Claire M McDaniel; Uma Srikumaran; Adam S Levin; Carol D Morris
Journal:  Clin Orthop Relat Res       Date:  2022-01-01       Impact factor: 4.755

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.